Your browser doesn't support javascript.
loading
Analysis of sociodemographic and clinical factors associated with Lassa fever disease and mortality in Nigeria.
Olayinka, Adebola T; Elimian, Kelly; Ipadeola, Oladipupo; Dan-Nwafor, Chioma; Gibson, Jack; Ochu, Chinwe; Furuse, Yuki; Iniobong, Akanimo; Akano, Adejoke; Enenche, Lorna; Onoja, Michael; Uzoho, Chukwuemeka; Ugbogulu, Nkem; Makava, Favour; Arinze, Chinedu; Namara, Geoffrey; Muwanguzi, Esther; Jan, Kamji; Ukponu, Winifred; Okwor, Tochi; Anueyiagu, Chimezie; Saleh, Muhammad; Ahumibe, Anthony; Eneh, Chibuzo; Ilori, Elsie; Mba, Nwando; Ihekweazu, Chikwe.
Afiliação
  • Olayinka AT; World Health Organisation, Abuja, FCT, Nigeria.
  • Elimian K; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Ipadeola O; Centers for Disease Prevention and Control, Abuja, Nigeria.
  • Dan-Nwafor C; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Gibson J; University of Nottingham, Nottingham, United Kingdom.
  • Ochu C; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Furuse Y; World Health Organisation, Abuja, FCT, Nigeria.
  • Iniobong A; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Akano A; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Enenche L; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Onoja M; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Uzoho C; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Ugbogulu N; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Makava F; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Arinze C; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Namara G; World Health Organisation, Abuja, FCT, Nigeria.
  • Muwanguzi E; World Health Organisation, Abuja, FCT, Nigeria.
  • Jan K; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Ukponu W; Georgetown University Centre for Global Health Practice and Impact, Abuja, Nigeria.
  • Okwor T; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Anueyiagu C; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Saleh M; Centers for Disease Prevention and Control, Abuja, Nigeria.
  • Ahumibe A; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Eneh C; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Ilori E; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Mba N; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
  • Ihekweazu C; Nigeria Centre for Disease Control, Abuja, FCT, Nigeria.
PLOS Glob Public Health ; 2(8): e0000191, 2022.
Article em En | MEDLINE | ID: mdl-36962735
Over past decades, there has been increasing geographical spread of Lassa fever (LF) cases across Nigeria and other countries in West Africa. This increase has been associated with significant morbidity and mortality despite increasing focus on the disease by both local and international scientists. Many of these studies on LF have been limited to few specialised centres in the country. This study was done to identify sociodemographic and clinical predictors of LF disease and related deaths across Nigeria. We analysed retrospective surveillance data on suspected LF cases collected during January-June 2018 and 2019. Multivariable logistic regression analyses were used to identify the factors independently associated with laboratory-confirmed LF diagnosis, and with LF-related deaths. There were confirmed 815 of 1991 suspected LF cases with complete records during this period. Of these, 724/815 confirmed cases had known clinical outcomes, of whom 100 died. LF confirmation was associated with presentation of gastrointestinal tract (aOR 3.47, 95% CI: 2.79-4.32), ear, nose and throat (aOR 2.73, 95% CI: 1.80-4.15), general systemic (aOR 2.12, 95% CI: 1.65-2.70) and chest/respiratory (aOR 1.71, 95% CI: 1.28-2.29) symptoms. Other factors were being male (aOR 1.32, 95% CI: 1.06-1.63), doing business/trading (aOR 2.16, 95% CI: 1.47-3.16) and farming (aOR 1.73, 95% CI: 1.12-2.68). Factors associated with LF mortality were a one-year increase in age (aOR 1.03, 95% CI: 1.01-1.04), bleeding (aOR 2.07, 95% CI: 1.07-4.00), and central nervous manifestations (aOR 5.02, 95% CI: 3.12-10.16). Diverse factors were associated with both LF disease and related death. A closer look at patterns of clinical variables would be helpful to support early detection and management of cases. The findings would also be useful for planning preparedness and response interventions against LF in the country and region.

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies / Screening_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article